Clinical trial
A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART
NCT00757250 is registered in ClinicalTrials.gov with US Biotest, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART
- Lead sponsor
- US Biotest, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- September 30, 2008
- Completion date
- December 31, 2011
- Enrollment
- 13 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.